News | December 19, 2025
ystral expands in India with new Bangalore facility, boosting team & local production
The expansion includes a larger technical and service team and increased local procurement
The expansion includes a larger technical and service team and increased local procurement
The Signals Xynthetica solution brings AI-driven in-silico generation, predictive modeling, and experimental validation into a single, governed environment
Alphyn is developing Zabalafin Hydrogel as the first therapy to simultaneously tackle the interconnected drivers of AD
More than five drug candidates from his team progressed to human trials including drugs like Rilematovir (Phase IIb), and Bedaquiline
All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed
The U.S. oncology market is projected to soar from $81 billion in 2025 to $212 billion by 2034
The companies aim to expand treatment options for millions living with metabolic disorders
This strategic investment aims to bolster the company's position as a global leader in Vitamin D3 manufacturing
_256_384.jpg)
Tirzepatide is the first and only dual agonist glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
It's a development that marks a potential breakthrough for people living with the rare and debilitating disease Duchenne muscular dystrophy (DMD)
Subscribe To Our Newsletter & Stay Updated
